Cargando…

Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data

PURPOSE: The International Neonatal Consortium recently published a proposed retinopathy of prematurity (ROP) activity scale intended for use in clinical trials after validation. The aim of this study was to validate the ROP activity scale (ROP-ActS) in a ROP screened cohort with protocol based coll...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivodic, Aldina, Nilsson, Staffan, Stahl, Andreas, Smith, Lois E.H., Hellström, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626862/
https://www.ncbi.nlm.nih.gov/pubmed/32592272
http://dx.doi.org/10.1111/aos.14532
_version_ 1784606740972568576
author Pivodic, Aldina
Nilsson, Staffan
Stahl, Andreas
Smith, Lois E.H.
Hellström, Ann
author_facet Pivodic, Aldina
Nilsson, Staffan
Stahl, Andreas
Smith, Lois E.H.
Hellström, Ann
author_sort Pivodic, Aldina
collection PubMed
description PURPOSE: The International Neonatal Consortium recently published a proposed retinopathy of prematurity (ROP) activity scale intended for use in clinical trials after validation. The aim of this study was to validate the ROP activity scale (ROP-ActS) in a ROP screened cohort with protocol based collected data by evaluating the ability of the ROP-Act scores to predict ROP treatment. In addition, we aimed to evaluate the scale’s sensitivity characteristic of disease severity by studying association with gestational age (GA) in comparison with conventionally used ROP stage and zone. METHODS: A cohort of 535 preterm infants with 3324 ROP examinations with an end-point of ROP treatment or end of screening in Gothenburg, Sweden, was included. Median GA was 28.1 weeks, 47.5% were girls, and 74 (13.8%) infants were treated for ROP. The validation was performed by estimating probabilities for ROP treatment, and by applying logistic and linear regression. RESULTS: The original ROP-ActS was overall well-ordered with respect to ability to predict ROP treatment but could be improved by re-ordering score 3 (zone II stage 1) and 5 (zone III stage 3) based on our clinical cohort data. The modified ROP-ActS was superior to ROP stage and zone in the prediction analysis of ROP treatment. Modified ROP-ActS was more strongly related to GA than currently used ROP stage, but not zone. CONCLUSION: In the studied cohort, the modified ROP-ActS could better predict ROP treatment compared to ROP stage and zone. Retinopathy of Prematurity Activity Scale (ROP-ActS) had a superior sensitivity characteristic studied through association to GA than conventionally used ROP stage.
format Online
Article
Text
id pubmed-8626862
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-86268622021-11-27 Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data Pivodic, Aldina Nilsson, Staffan Stahl, Andreas Smith, Lois E.H. Hellström, Ann Acta Ophthalmol Article PURPOSE: The International Neonatal Consortium recently published a proposed retinopathy of prematurity (ROP) activity scale intended for use in clinical trials after validation. The aim of this study was to validate the ROP activity scale (ROP-ActS) in a ROP screened cohort with protocol based collected data by evaluating the ability of the ROP-Act scores to predict ROP treatment. In addition, we aimed to evaluate the scale’s sensitivity characteristic of disease severity by studying association with gestational age (GA) in comparison with conventionally used ROP stage and zone. METHODS: A cohort of 535 preterm infants with 3324 ROP examinations with an end-point of ROP treatment or end of screening in Gothenburg, Sweden, was included. Median GA was 28.1 weeks, 47.5% were girls, and 74 (13.8%) infants were treated for ROP. The validation was performed by estimating probabilities for ROP treatment, and by applying logistic and linear regression. RESULTS: The original ROP-ActS was overall well-ordered with respect to ability to predict ROP treatment but could be improved by re-ordering score 3 (zone II stage 1) and 5 (zone III stage 3) based on our clinical cohort data. The modified ROP-ActS was superior to ROP stage and zone in the prediction analysis of ROP treatment. Modified ROP-ActS was more strongly related to GA than currently used ROP stage, but not zone. CONCLUSION: In the studied cohort, the modified ROP-ActS could better predict ROP treatment compared to ROP stage and zone. Retinopathy of Prematurity Activity Scale (ROP-ActS) had a superior sensitivity characteristic studied through association to GA than conventionally used ROP stage. 2020-06-26 2021-03 /pmc/articles/PMC8626862/ /pubmed/32592272 http://dx.doi.org/10.1111/aos.14532 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Pivodic, Aldina
Nilsson, Staffan
Stahl, Andreas
Smith, Lois E.H.
Hellström, Ann
Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data
title Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data
title_full Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data
title_fullStr Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data
title_full_unstemmed Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data
title_short Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data
title_sort validation of the retinopathy of prematurity activity scale (rop-acts) using retrospective clinical data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626862/
https://www.ncbi.nlm.nih.gov/pubmed/32592272
http://dx.doi.org/10.1111/aos.14532
work_keys_str_mv AT pivodicaldina validationoftheretinopathyofprematurityactivityscaleropactsusingretrospectiveclinicaldata
AT nilssonstaffan validationoftheretinopathyofprematurityactivityscaleropactsusingretrospectiveclinicaldata
AT stahlandreas validationoftheretinopathyofprematurityactivityscaleropactsusingretrospectiveclinicaldata
AT smithloiseh validationoftheretinopathyofprematurityactivityscaleropactsusingretrospectiveclinicaldata
AT hellstromann validationoftheretinopathyofprematurityactivityscaleropactsusingretrospectiveclinicaldata